These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10565855)

  • 1. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
    Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
    Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
    Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
    Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
    Hennessy M; Clarke S; Spiers JP; Mulcahy F; Kelleher D; Meadon E; Maher B; Bergin C; Khoo S; Tjia J; Hoggard P; Back D; Barry M
    Antivir Ther; 2003 Jun; 8(3):191-8. PubMed ID: 12924535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HIV agents. TXU-PAP--early results.
    TreatmentUpdate; 2000 Feb; 12(1):2. PubMed ID: 12125626
    [No Abstract]   [Full Text] [Related]  

  • 8. Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1.
    Rajamohan F; Venkatachalam TK; Irvin JD; Uckun FM
    Biochem Biophys Res Commun; 1999 Jul; 260(2):453-8. PubMed ID: 10403789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
    N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.
    Jacobson JM; Lowy I; Fletcher CV; O'Neill TJ; Tran DN; Ketas TJ; Trkola A; Klotman ME; Maddon PJ; Olson WC; Israel RJ
    J Infect Dis; 2000 Jul; 182(1):326-9. PubMed ID: 10882617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
    Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
    AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity.
    Gordon M; Deeks S; De Marzo C; Goodgame J; Guralnik M; Lang W; Mimura T; Pearce D; Kaneko Y
    J Med; 1997; 28(1-2):108-28. PubMed ID: 9249617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy.
    García F; Vidal C; Plana M; Cruceta A; Gallart MT; Pumarola T; Miro JM; Gatell JM
    Clin Infect Dis; 2000 Feb; 30(2):392-4. PubMed ID: 10671348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies.
    Zarling JM; Moran PA; Haffar O; Sias J; Richman DD; Spina CA; Myers DE; Kuebelbeck V; Ledbetter JA; Uckun FM
    Nature; 1990 Sep; 347(6288):92-5. PubMed ID: 1975641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
    Shearer WT; Israel RJ; Starr S; Fletcher CV; Wara D; Rathore M; Church J; DeVille J; Fenton T; Graham B; Samson P; Staprans S; McNamara J; Moye J; Maddon PJ; Olson WC
    J Infect Dis; 2000 Dec; 182(6):1774-9. PubMed ID: 11069253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.